Allergan
This article was originally published in The Gray Sheet
Executive Summary
Completes the divestiture of its contact lens business with the sale of contact lens operations outside the Americas to U.K.- based Hydron. In late 1992, the firm sold its North and South American contact lens business to Ocular Sciences ("The Gray Sheet" Nov. 9, I&W-13). Terms of the Hydron transaction were not disclosed, but Allergan reports that "an immaterial gain was realized." Allergan President and CEO William Shepherd said that the firm "remain[s] committed" to its contact lens care products business.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.